Premier Biomedical Inc (BIEI)

[Opportunity Strikes]

December 08, 2015 12:00 PM Eastern Standard Time


EL PASO, Texas--(BUSINESS WIRE)--Premier Biomedical, Inc. (OTCQB:BIEI) a biotech research company focused on discovering, developing, and commercializing medical treatments for a wide range of diseases in humans, including innovative therapies for breast cancer, announced today that one of the lead outside scientists working on their sponsored research has been invited to present his findings on the treatment of breast cancer, at an evening educational session sponsored by prIME Oncology, at the San Antonio Breast Cancer Symposium December 9, 2015.

Researchers have previously presented positive results from the application of breast cancer antibodies along with Premier Biomedical’s technology in duplicated testing on mice at the American Association for Cancer Research annual meeting in San Diego in April, 2014. These results showed statistically significant improvements in survival and prevention of breast cancer in mice treated with innovative anti-breast cancer treatment versus chemotherapy-only and non-treated groups. Most significantly, the research has shown the prevention of breast cancer metastasis in mice with the jointly developed breast cancer antibody.

William A. Hartman, President and CEO of Premier Biomedical stated, “We have always believed we were working with leading researchers in the field of breast cancer treatment. This invitation to present the underpinnings of that work at this educational session during the San Antonio Breast Cancer Symposium is an indication that our beliefs were well founded. Our research has already led to a patent-pending breast cancer antibody which has been demonstrated to be approximately three times more effective than the successful antibody we previously presented to the American Association for Cancer Research Symposium in April, 2014. We are extremely excited to have found what we consider to be a huge anti-breast cancer breakthrough.”

Mr. Hartman can be contacted via email at [e-mail] or by phone at (PBI) MED-7033 / [phone]
http://www.businesswire.com/news/home/20151208005481/en/